JPRN-jRCT1080224586已完成1 期
A single-center, open-label, randomized, 3-arm, 3-way, crossover trial to investigate the bioequivalence of brexpiprazole (OPC-34712) orally disintegrating tablets in healthy adult males
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 41
研究概览
简要总结
It was concluded that brexpiprazole 2mg ODT was bioequivalent to brexpiprazole 2mg conventional tablet. There were no marked differences in safety and tolerability between the brexpiprazole ODT and conventional tablet.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 39age old（—）
- 性别
- Male
入选标准
- •1.Body mass index [BMI = body weight in kg /(height in m)2] of at least 18.5 kg/m2 and less than 25.0 kg/m2 (as a result of at the screening examination)
- •2.Capable of providing written informed consent before commencement of any trial-related procedures, and able, in the opinion of the investigator, to comply with all requirements of the trial.
排除标准
- •1.Clinically significant abnormality at the time of screening (eg, significant deviation from reference ranges) or in medical history that, in the opinion of investigator, subinvestigator, or sponsor may place the subject at risk or interfere with outcome variables such as drug absorption, distribution, metabolism, and excretion
- •2.History of serious mental disorder
- •3.History of drug or alcohol abuse within 2 years prior to screening
- •4.History of any significant drug allergy
- •5.Use of another investigational drug within 120 days prior to the first administration of IMP
- •6.Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange products, star fruit, or star fruit products within 72 hours prior to the first administration of IMP or consumption of alcohol within 72 hours prior to administration of IMP.
- •7.Use of prescription, over-the-counter (OTC), or herbal medication, or vitamin supplements, or consumption of food or beverages containing St. John's Wort within 14 days prior to the first administration of IMP, or use of antibiotics within 30 days prior to the first administration of IMP.
- •8.History of major surgery of the digestive tract (excluding appendectomy)
- •9.Any subject who, in the judgement of the investigator or subinvestigator, should not participate in the trial.
研究者
相似试验
已完成
1 期
Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mgHealthy Adult MaleNCT03902574Otsuka Pharmaceutical Co., Ltd.21
已完成
1 期
Clinical pharmacology study of brexpiprazole (OPC-34712) once-weekly (QW) formulation for schizophreniaSchizophreniaJPRN-jRCT2080223873Otsuka Pharmaceutical Co., Ltd.25
已完成
3 期
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious DistressDepressive DisorderDepressive Disorder, MajorMood DisordersMental DisordersDepressionNCT02196506Otsuka Pharmaceutical Development & Commercialization, Inc.837
已完成
3 期
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.Acute ManiaBipolar I DisorderNCT03287869Otsuka Pharmaceutical Development & Commercialization, Inc.381
已完成
3 期
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With SchizophreniaAcute SchizophreniaNCT01668797Otsuka Pharmaceutical Development & Commercialization, Inc.524